Occurrence and clinical course of immune checkpoint inhibitor-associated inflammatory arthritis and polymyalgia rheumatica-like syndromes: a systematic review and meta-analysis
- 1Fujian University of Traditional Chinese Medicine , , ,
- 2Luoyang Orthopedic-Traumatological Hospital of Henan Province (Henan Provincial Orthopedic Hospital) , ,
Abstract
Background: Immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) and polymyalgia rheumatica (PMR)-like syndromes are clinically important rheumatic immune-related adverse events, but definitions vary across studies. We estimated their occurrence in real-world cohorts and summarized clinical course and management.
Methods: PubMed, Ovid MEDLINE, Embase, Web of Science Core Collection, and Cochrane CENTRAL were searched from inception through July 25, 2026. Two reviewers independently screened studies, extracted data, and assessed risk of bias, with disagreements resolved by a third reviewer. Compatible single-group proportions were pooled using random-intercept binomial generalized linear mixed models; non-poolable clinical-course evidence was synthesized using the Synthesis Without Meta-analysis framework.
Results: Sixty-five reports representing 63 studies were included. Five independent ICI-treated cohorts reported 140 study-defined de novo ICI-IA cases among 4,644 patients, yielding a pooled crude occurrence proportion of 2.87% (95% CI, 2.02%-4.07%; 95% prediction interval, 1.06%-7.53%; I ² = 71.7%). Three of the five primary cohorts were at high risk of bias. Definitions varied; excluding the largest cohort, which used a broader clinician-suspected joint-symptom definition, yielded a pooled proportion of 2.61% (95% CI, 1.50%-4.79%). Three studies reported 19 PMR/PMR-like events among 1,998 patients (1.08%; 95% CI, 0.32%-3.62%), with marked imprecision and heterogeneity. A 2026 cohort reporting 12 PMR cases among 734 patients was retained as contextual evidence because de novo timing could not be verified and possible overlap with an earlier report could not be excluded. Descriptive evidence showed heterogeneous phenotypes and disease courses, with persistence in some cohorts and remission in others. Glucocorticoids and disease-modifying antirheumatic drugs were frequently used, but comparative treatment effects could not be determined.
Conclusion: In denominator-valid studies, approximately 3% of ICI-treated patients were classified as having de novo ICI-IA during variable study-specific follow-up. This is a crude study-period proportion, not a fixed-time incidence risk. Standardized definitions and prospective denominator-valid cohorts are needed.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261460334 , identifier CRD420261460334.
Related
- The 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica
- More is less: Glucocorticoid-sparing agents in polymyalgia rheumatica
- Polymyalgia Rheumatica or Something Else? Bilateral Shoulder, Arm, and Thigh Pain with Diffuse Marrow Edema Revealing B-cell Acute Lymphoblastic Leukemia
- Imaging for diagnosis, monitoring and outcome prediction in polymyalgia rheumatica: a systematic literature review and meta-analysis informing an international task force
- Influence of Sex on Glucocorticoid Toxicity Profiles in Polymyalgia Rheumatica
BibTeX
@article{li2026occurrence,
title = {{Occurrence and clinical course of immune checkpoint inhibitor-associated inflammatory arthritis and polymyalgia rheumatica-like syndromes: a systematic review and meta-analysis}},
author = {Chenyang Li and Ruhui Fu and Xinxin Geng and Yunru Zhang and Qiang Yuan and Peifeng Li and Yanan Fan and Ying Zhang},
journal = {Frontiers in immunology},
year = {2026},
month = sep,
doi = {10.3389/fimmu.2026.1959233},
url = {https://europepmc.org/article/PMC/PMC13662647},
note = {CC BY},
}
RIS
TY - JOUR
TI - Occurrence and clinical course of immune checkpoint inhibitor-associated inflammatory arthritis and polymyalgia rheumatica-like syndromes: a systematic review and meta-analysis
AU - Chenyang Li
AU - Ruhui Fu
AU - Xinxin Geng
AU - Yunru Zhang
AU - Qiang Yuan
AU - Peifeng Li
AU - Yanan Fan
AU - Ying Zhang
PY - 2026
DA - 2026/09/30
JO - Frontiers in immunology
DO - 10.3389/fimmu.2026.1959233
UR - https://europepmc.org/article/PMC/PMC13662647
AB - Background: Immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) and polymyalgia rheumatica (PMR)-like syndromes are clinically important rheumatic immune-related adverse events, but definitions vary across studies. We estimated their occurrence in real-world cohorts and summarized clinical course and management. Methods: PubMed, Ovid MEDLINE, Embase, Web of Science Core Collection, and Cochrane CENTRAL were searched from inception through July 25, 2026. Two reviewers independently screened studies, extracted data, and assessed risk of bias, with disagreements resolved by a third reviewer. Compatible single-group proportions were pooled using random-intercept binomial generalized linear mixed models; non-poolable clinical-course evidence was synthesized using the Synthesis Without Meta-analysis framework. Results: Sixty-five reports representing 63 studies were included. Five independent ICI-treated cohorts reported 140 study-defined de novo ICI-IA cases among 4,644 patients, yielding a pooled crude occurrence proportion of 2.87% (95% CI, 2.02%-4.07%; 95% prediction interval, 1.06%-7.53%; I ² = 71.7%). Three of the five primary cohorts were at high risk of bias. Definitions varied; excluding the largest cohort, which used a broader clinician-suspected joint-symptom definition, yielded a pooled proportion of 2.61% (95% CI, 1.50%-4.79%). Three studies reported 19 PMR/PMR-like events among 1,998 patients (1.08%; 95% CI, 0.32%-3.62%), with marked imprecision and heterogeneity. A 2026 cohort reporting 12 PMR cases among 734 patients was retained as contextual evidence because de novo timing could not be verified and possible overlap with an earlier report could not be excluded. Descriptive evidence showed heterogeneous phenotypes and disease courses, with persistence in some cohorts and remission in others. Glucocorticoids and disease-modifying antirheumatic drugs were frequently used, but comparative treatment effects could not be determined. Conclusion: In denominator-valid studies, approximately 3% of ICI-treated patients were classified as having de novo ICI-IA during variable study-specific follow-up. This is a crude study-period proportion, not a fixed-time incidence risk. Standardized definitions and prospective denominator-valid cohorts are needed. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261460334 , identifier CRD420261460334.
SN - 1664-3224
ER -